Astria Therapeutics, Inc. (ATXS)
Jan 26, 2026 - ATXS was delisted (reason: acquired by BCRX)
12.58
0.00 (0.00%)
Inactive · Last trade price on Jan 22, 2026

Astria Therapeutics Stock Forecast

Stock Price Forecast

The 6 analysts with 12-month price forecasts for Astria Therapeutics stock had an average target of $24.33, with a low estimate of $13 and a high estimate of $47.

Price Target: $24.33 (+93.40%)
Analyst Consensus: Hold

Price Target

TargetLowAverageMedianHigh
Price$13$24.33n/a$47
Change+3.34%+93.40%n/a+273.61%

Analyst Ratings

The average analyst rating for Astria Therapeutics stock from 6 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.

Recommendation Trends

No data available
RatingOct 2026
Strong Buyn/a
Buyn/a
Holdn/a
Selln/a
Strong Selln/a
Totaln/a

Financial Forecast

Revenue This Year
8.74M
Revenue Next Year
3.57M
from 8.74M
Decreased by -59.15%
EPS This Year
-2.20
from -1.68
EPS Next Year
-2.27
from -2.20
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
-----8.74M3.57M
Revenue Growth
-------59.15%
EPS
-12.20-24.58-3.55-2.42-1.68-2.20-2.27
No. Analysts
-----109

Revenue Forecast

Revenue202520262027202820292030
High16.8M8.4M
Avg8.7M3.6M
Lown/an/a

Revenue Growth

Revenue Growth202520262027202820292030
High-
-3.9%
Avg-
-59.2%
Low--

EPS Forecast

EPS202520262027202820292030
High-1.94-1.73
Avg-2.20-2.27
Low-2.48-2.69

EPS Growth

EPS Growth202520262027202820292030
High--
Avg--
Low--